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Abstract
The risk factors and clinical features of patients with Candida tropicalis fungaemia have not been fully deﬁned. We performed a case–con-
trol study comparing 59 cases of C. tropicalis fungaemia with 177 episodes of fungaemia caused by other species of Candida in our hospi-
tal over a 24-year period (January 1985 to December 2008). Patients with C. tropicalis fungaemia were more likely to be older (median
age, 67 vs. 56 years; p 0.01), to have cancer (45.5% vs. 31.6%, p 0.04), and to have the abdomen as the portal of entry (32.2% vs.
11.9%, p 0.001), and had a higher in-hospital mortality rate (61% vs. 44%, p 0.03). Multivariate analysis showed that the independent risk
factors for C. tropicalis fungaemia were cancer (OR 4.5; 95% CI 1.05–3.83; p 0.03) and the abdomen as the portal of entry (OR 13.6;
95% CI 1.9–8.2; p <0.001). When survivors were compared with non-survivors, the risk factors associated with a poor outcome were
neutropenia (19.4% vs. 0; p 0.03), corticosteroid treatment (36% vs. 13%; p 0.07), and septic shock (50% vs. 17.4%; p 0.01). The inde-
pendent risk factors for mortality in the multivariate analysis were corticosteroid treatment (OR 8.2; 95% CI 0.9–27.7; p 0.04) and sep-
tic shock (OR 14.6; 95% CI 2.4–90.2; p 0.004), whereas urinary tract infection (OR 0.07; 95% CI 0.01–0.8; p 0.03) and catheter removal
(OR 0.06; 95% CI 0.01–0.4; p 0.002) were protective factors. C. tropicalis is the fourth most common cause of fungaemia in our hospital.
It is associated with underlying malignancy, the abdomen as the portal of entry, and poor outcome.
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Introduction
Candidaemia is a major cause of morbidity and mortality in
the healthcare setting. Candida species now rank fourth in
the USA and sixth in Europe among causes of nosocomial
bloodstream infection (BSI) [1–3]. In addition, the crude
mortality rate of candidaemia is approximately 40–50%,
depending on the population and the species studied [4–6].
In recent years, there has been an increase in the inci-
dence of candidaemia and a shift towards Candida species
other than Candida albicans, with Candida parapsilosis, Candida
glabrata, Candida krusei and Candida tropicalis causing almost
half of all episodes [5–12]. C. parapsilosis has been related to
overuse of venous catheters, especially in neonates, trans-
plant recipients, and patients receiving parenteral nutrition
[13]. The emergence of C. glabrata and C. krusei has been
related to antifungal exposure in speciﬁc populations, such as
elderly patients, solid organ recipients, patients with neutro-
penia, patients receiving corticosteroids, and neonates [5]. In
contrast, the clinical features of patients with candidaemia
caused by C. tropicalis are poorly deﬁned and usually biased
by the selection of speciﬁc groups, such as patients with hae-
matological malignancies or solid tumours [14–16]. In addi-
tion, data on incidence and mortality vary with the country
and the population studied.
We performed the largest single-centre case–control
study to date of patients with C. tropicalis fungaemia, in order
to deﬁne the risk factors and outcome of this condition in
an unselected population.
Materials and Methods
Study design and setting
We performed a case–control study comparing each patient
who had had an episode of C. tropicalis fungaemia with three
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cases of fungaemia caused by other species in our institution
from January 1985 to December 2008. The controls were
matched only by the year of isolation of non-tropicalis Can-
dida species from blood, and were selected from the data-
base by means of a random number table.
Ours is a large, general tertiary teaching hospital currently
serving a population of approximately 750 000 inhabitants in
Madrid, Spain. The hospital has approximately 1600 beds and
all medical and surgical specialties, including solid organ
(heart, liver, and kidney) and bone marrow transplant pro-
grammes.
Clinical data and deﬁnitions
The medical charts of the patients were retrospectively
reviewed according to a pre-established protocol including
the following variables: age, sex, underlying diseases, risk fac-
tors, clinical presentation, source of fungaemia, antifungal
therapy, mortality during admission, and mortality attribut-
able to candidaemia.
An episode of candidaemia was deﬁned as at least one
blood culture that was positive for Candida. Among underly-
ing diseases, cancer refers to patients with an active tumour
at the onset of candidaemia, haematological disease refers to
patients with a haematological malignancy at the onset of
candidaemia, human immunodeﬁciency virus (HIV) refers to
patients with HIV infection, with or without AIDS, intrave-
nous drug abuse (IVDA) refers to patients who were actively
using illicit intravenous drugs at the onset of candidaemia,
and transplantation refers to patients who were recipients of
haematological or solid organ transplants.
Regarding risk factors, neutropenia refers to patients who
presented an absolute neutrophil count <500 cells/mm3 at
the onset of candidaemia. Intensive-care unit stay, parenteral
nutrition, intravenous lines and bladder catheters were con-
sidered to be risk factors if they were present at the onset
of candidaemia. Corticosteroid use was assumed to be a risk
factor if the patient had received ‡20 mg/day of prednisone
for ‡15 days before the onset of fungaemia. Previous therapy
with antimicrobials, antifungals and azoles was deﬁned as the
administration of one or more doses of each agent during
the 30 days before the onset of candidaemia. Surgery refers
to any type of major surgical procedure in the past
3 months.
With regard to clinical manifestations, fever was deﬁned
as an axillary temperature ‡38.3C. Septic shock was deﬁned
as refractory hypotension despite adequate ﬂuid resuscitation
and cardiac output [17]. Renal failure was deﬁned as a creati-
nine level ‡1.5 mg/dL.
The abdomen was considered to be the portal of entry in
patients undergoing gastrointestinal surgery, patients under-
going peritoneal dialysis, and patients with an abdominal per-
foration and no other apparent source of BSI. For an
episode to be included as catheter-related candidaemia, we
followed the guidelines of the Infectious Diseases Society of
America [18]. The urinary tract was considered to be the
portal of entry in patients with obstructive uropathy and evi-
dence of urinary tract infection caused by the same species
of Candida.
We deﬁned related mortality as death occurring within
5 days after diagnosis, with concurrent signs of active
infection. Crude mortality was deﬁned as mortality during
admission.
Microbiological identiﬁcation and antifungal susceptibility
testing
From 1985 to October 1995, blood samples were processed
with the automated BACTEC-NR system (Becton Dickinson,
Cockeysville, MD, USA), and thereafter they were processed
with the BACTEC-9240 system (Becton Dickinson). During
the ﬁrst period, all vials were incubated at 35C for 7 days,
and in the second period, vials were shaken continuously for
5 days. CHROMagar Candida (CHROMagar, Paris, France), a
differential and selective chromogenic agar medium for
yeasts, was introduced in our institution in 1995. Since then,
the yeast isolates have been systematically subcultured onto
CHROMagar Candida plates and incubated for 5 days at
35C to identify possible mixed infections. Identiﬁcation of
the isolates was conﬁrmed with the ID 32C system (bio-
Me´rieux, St Louis, MO, USA), according to the manufac-
turer’s recommendations. Isolates recovered from blood
cultures were stored at )70C.
We studied the antifungal activity of amphotericin B, 5-ﬂu-
orocytosine, ketoconazole, ﬂuconazole, itraconazole, and
voriconazole against the clinical isolates. The susceptibility
study was performed with Sensititre YeastOne (Trek Diag-
nostic Systems, Cleveland, OH, USA), a modiﬁed microdilu-
tion method, according to the recommendations of the CLSI
(M27-A2) [19,20]. The trays were incubated for 24–48 h at
35C. Endpoint readings were deﬁned visually as full inhibi-
tion of growth (amphotericin B) or prominent inhibition of
growth (all other antifungals). We used the breakpoints pro-
posed by CLSI M27-S3, as follows: ﬂuconazole, susceptible
£8 mg/L, susceptible–dose-dependent 16–32 mg/L,, and resis-
tant ‡64 mg/L; voriconazole, susceptible £1 mg/L,, suscepti-
ble–dose-dependent 2 mg/L, and resistant ‡4 mg/L;
caspofungin, susceptible £2 mg/L, and non-susceptible ‡4 mg/
L; ﬂucytosine, susceptible £4 mg/L, intermediate 8–16 mg/L,
and resistant ‡32 mg/L; and itraconazole, susceptible
£0.125 mg/L, susceptible–dose-dependent 0.25–0.5 mg/L, and
resistant ‡1 mg/L.
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Data analysis
We calculated the incidence of C. tropicalis fungaemia as the
number of episodes detected each year divided by the num-
ber of inhabitants (in hundreds of thousands) in our refer-
ence area, and by the number of hospital admissions (in
thousands). The incidence of C. tropicalis BSI during the study
period was measured by use of the autoregressive integrated
moving average test, with data in monthly intervals. This
model was adjusted for the blood culture system used in
each period and the percentage of blood cultures with
growth of signiﬁcant microorganisms (as a measurement of
index of suspicion). A p-value <0.05 was considered to indi-
cate signiﬁcance. The analysis was carried out with SPSS 15.0
(SPSS, Chicago, IL, USA).
In the univariate analysis of cases and controls, categorical
variables were compared by use of the chi-square test. Non-
normally distributed continuous variables were compared by
use of Student’s t-test, and approximately normally distrib-
uted variables were compared by use of Student’s t-test or
analysis of variance. Stepwise logistic regression models were
applied in the multivariate analysis to control for potential
confounders and for risk factors of mortality. Variables with
a p-value <0.1 in the univariate analysis were included in the
multivariate models. Differences were considered to be sig-
niﬁcant for p-values <0.05. The analysis was carried out with
SPSS 15.0 (SPSS).
Results
Between January 1985 and December 2008, we detected
970 episodes of fungaemia (3% of all episodes of signiﬁcant
BSI in our hospital): 448 were caused by C. albicans, 324 by
C. parapsilosis, 78 by C. glabrata, 68 by C. tropicalis, 15 by
C. krusei, and 37 by other species. The incidence of C. tropi-
calis BSI in our institution increased at an annual rate
of 0.003 episodes/1000 admissions and 0.029 episodes/
100 000 inhabitants, although the trend was not statistically
signiﬁcant (p 0.211 and p 0.116, respectively) (Table 1).
Of the 68 patients with C. tropicalis fungaemia, clinical
data were fully available only for 59. These 59 patients
(cases) were compared with 177 patients with fungaemia
caused by other species (controls). In controls, the distri-
bution of species was as follows: C. albicans in 67 patients
(37.8%), C. parapsilosis in 40 (22.5%), C. glabrata in 37
(20.9%), mixed fungaemia in 14 (7.9%), C. krusei in 12
(6.7%), Candida dubliniensis in three (1.7%), Candida guillier-
mondii in two (1.1%), and Saccharomyces cerevisiae in two
(1.1%).
Patients with C. tropicalis fungaemia were older (median,
67 vs. 56 years; p 0.01), had a higher incidence of cancer
(49.2% vs. 32.8%; p 0.03) and had a lower incidence of HIV
infection (5% vs. 17%; p 0.03) than controls (Table 2). No





C. tropicalis BSI per
100 000 inhabitants Admissions
C. tropicalis BSI per
1000 admissions
1985 0 605 000 0 49 330 0
1986 0 608 594 0 50 365 0
1987 2 612 284 0.32 49 367 0.04
1988 1 615 974 0.16 48 558 0.02
1989 0 619 664 0 47 789 0
1990 6 623 354 0.96 46 443 0.13
1991 0 627 043 0 45 792 0
1992 2 629 040 0.31 45 565 0.04
1993 1 631 037 0.15 48 582 0.02
1994 3 633 034 0.47 48 275 0.06
1995 0 635 031 0 47 972 0
1996 4 637 028 0.62 49 687 0.08
1997 2 642 091 0.31 51 604 0.03
1998 3 647 154 0.46 50 371 0.06
1999 5 650 597 0.76 49 097 0.1
2000 5 653 849 0.76 50 873 0.09
2001 2 668 942 0.29 52 249 0.04
2002 3 684 754 0.43 52 889 0.05
2003 4 704 030 0.56 54 781 0.07
2004 3 717 326 0.41 61 299 0.05
2005 1 738 481 0.13 62 773 0.01
2006 9 743 387 1.21 65 681 0.13
2007 6 752 687 0.79 67 882 0.08
2008 6 777 784 0.77 58 724 0.1
Annual average 2.83 610 767 0.46 50 481 0.056
Annual increase – – 0.029 – 0.003
p – – 0.116 – 0.211
BSI, bloodstream infection.
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signiﬁcant differences were found between the groups for
other risk factors and clinical manifestations. The most com-
mon portals of entry were the abdomen among the cases
(32.2% vs. 11.9%; p 0.001) and a venous catheter among the
controls (23.7% vs. 44%; p 0.006). In 125 patients, the same
Candida species was isolated from sites other than blood,
with the same frequencies in cases and controls (49.2% vs.
54.2%; p 0.55). No signiﬁcant differences were found
between the groups for metastatic complications. With
regard to antifungal treatment, we found that the cases were
less likely to have received treatment (64.4% vs. 79%;
p 0.03). In 14 of the 21 untreated cases, antifungal therapy
was not started because the patient died before or on the
day when blood cultures became positive, or because the
prognosis was extremely poor. In-hospital mortality was
higher among patients with C. tropicalis fungaemia than among
controls (61% vs. 44%; p 0.03), and related mortality rates
were similar between the groups (30.5% vs. 29.4%; p 0.87).
The median time to death was 9 days (range, 0–74 days)
among patients with C. tropicalis fungaemia vs. 10 days
(range, 0–140 days) among those with fungaemia caused by
other species (p 0.56). The overall mortality rates at 15
and 30 days after the diagnosis of candidaemia were 64% and
80.6% among patients with C. tropicalis fungaemia vs. 68% and







(n = 177) p
Multivariate
analysis,
OR (95% CI), p
Age (years), mean ± SD (median, range) 59 ± 23 (67, 0–90) 49 ± 25 (56, 0–90) 0.01
Gender, no. (%)
Male 40 (67.8) 119 (67.2) 1
Female 19 (32.2) 58 (32.8)
Underlying disease, no. (%)
Cancer 29 (49.2) 58 (32.8) 0.03 4.5 (1.05–3.83), 0.03
Haematological disease 6 (10.2) 16 (9) 0.76
HIV 3 (5.1) 30 (17) 0.03
Injection drug use 4 (6.8) 21 (12) 0.33
Transplantation 3 (5.1) 12 (7.1) 0.76
Risk factor, no. (%)
Intensive-care unit 15 (25.4) 55 (31.1) 0.45
Neutropenia 7 (11.9) 13 (7.3) 0.27
Surgery 28 (47.5) 85 (48) 1
Parenteral nutrition 29 (49.2) 87 (49.2) 1
Intravenous lines 49 (83.1) 154 (87) 0.51
Bladder catheter 39 (66.1) 117 (66.1) 1
Previous antimicrobials 48 (81.4) 143 (80.8) 1
Previous antifungals 11 (18.6) 55 (31.1) 0.07
Previous azole agents 10 (16.9) 42 (23.7) 0.36
Corticosteroids 16 (27.1) 44 (24.9) 0.76
Clinical manifestations, no. (%)
Fever 46 (78) 146 (82.5) 0.44
Shock 22 (37.5) 53 (29.9) 0.33
Renal insufﬁciency 13 (22) 23 (13) 0.09
Source, no. (%)
Abdomen 19 (32.2) 21 (11.9) 0.001 13.6 (1.9–8.2), <0.001
Venous catheter 14 (23.7) 78 (44) 0.006
Unknown 18 (30.5) 54 (30.5) 1
Urine 7 (12) 11 (6.2) 0.16
Positive culture from sites other than blood, no. (%)
Urine 15 (25.4) 31 (17.5) 0.19
Venous catheter 11 (18.6) 49 (27.7) 0.23
Respiratory samplea 4 (6.8) 21 (11.9) 0.34
Abdominal sampleb 3 (5.1) 13 (7.3) 0.76
Wound 2 (3.4) 19 (10.7) 0.11
Cardiac valve 1 (1.7) 1 (0.6) 0.44
Metastatic complications, no. (%)
Skin and soft tissue 2 (3.4) 11 (6.2) 0.53
Ocular 1 (1.7) 11 (6.2) 0.30
Lung 2 (3.4) 6 (3.4) 1
Endocarditis 1 (1.7) 3 (1.7) 1
Liver 0 2 (1.1) 1
CNS 0 2 (1.1) 1
Received antifungal therapy, no. (%) 38 (64.4) 140 (79.1) 0.03
Time to treatment (days), mean ± SD (median, range) 0.95 ± 3.7 (1, )12 to 8) 1.02 ± 6.4 (2, )35 to 19) 0.9
Catheter withdrawal, no. (%) 25 (42.4) 93 (52.5) 0.2
Mortality, no. (%) 36 (61) 78 (44) 0.03
Related mortality, no. (%) 18 (30.5) 52 (29.4) 0.87
CNS, central nervous system; HIV, human immunodeﬁciency virus; SD, standard deviation.
aRespiratory samples include sputum (12), tracheobronchial aspirate (11), and pleural ﬂuid (two).
bAbdominal samples include peritoneal ﬂuid (nine), intra-abdominal abscess drainage (ﬁve), and biliary ﬂuid (two).
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84.6% among those with fungaemia caused by other species
(p 0.6).
The multivariate analysis revealed that the factors inde-
pendently associated with C. tropicalis fungaemia were cancer
(OR 4.5; 95% CI, 1.05–3.83; p 0.03) and the abdomen as the
portal of entry (OR 13.6; 95% CI 1.9–8.2; p <0.001). Of the
28 patients with cancer, 16 (57.1%) had gastrointestinal
involvement. Among the 19 patients in whom the abdomen
was the portal of entry, surgery (73.7%) and solid tumour
(57.1%) were the most common underlying conditions. Nine
patients underwent surgery for gastrointestinal cancer.
We also compared episodes of fungaemia caused by
C. tropicalis and C. albicans (Table 3). Patients with C. tropicalis
fungaemia were less frequently infected with HIV, and the
source was less commonly an intravenous catheter.
Susceptibility testing was performed on the 68 available
C. tropicalis strains (Table 4). With the exception of one iso-
late that was resistant to ﬂucytosine, all isolates were sus-
ceptible to the antifungal agents studied.
In order to analyse the factors associated with mortality
among patients with C. tropicalis fungaemia, we compared sur-
vivors with non-survivors. The univariate analysis showed that
neutropenia (19% vs. 0%; p 0.03), corticosteroid treatment
(36% vs. 13%; p 0.07) and septic shock (50% vs. 17.4%; p 0.01)
were more common among non-survivors (Table 5), whereas
HIV infection (0% vs. 13%; p 0.05), IVDA (0% vs. 17.4%;






(n = 67) p
Multivariate analysis,
OR (95% CI), p
Age (years), mean ± SD (median, range) 59 ± 23 (67, 0–90) 50 ± 24 (55, 0–90) 0.04
Gender, no. (%)
Male 40 (67.8) 48 (71.6) 0.69
Female 19 (32.2) 19 (28.4)
Underlying disease, no. (%)
Cancer 29 (49.2) 21 (31.3) 0.05
Haematological disease 6 (10.2) 4 (6) 0.5
HIV 3 (5.1) 17 (25.4) 0.003 0.17 (0.04–0.62), 0.008
Injection drug use 4 (6.8) 11 (16.4) 0.108
Transplantation 3 (5.1) 2 (3) 0.66
Risk factor, no. (%)
Intensive-care unit 15 (25.4) 24 (35.8) 0.25
Neutropenia 7 (11.9) 1 (1.5) 0.02
Surgery 28 (47.5) 29 (43.3) 0.72
Parenteral nutrition 29 (49.2) 34 (50.7) 1
Intravenous lines 49 (83.1) 60 (89.2) 0.31
Bladder catheter 39 (66.1) 43 (64.2) 0.85
Previous antimicrobials 48 (81.4) 53 (79) 0.82
Previous antifungals 11 (18.6) 17 (25.4) 0.39
Previous azole agents 10 (16.9) 12 (17.9) 1
Corticosteroids 16 (27.1) 10 (14.9) 0.12
Clinical manifestations, no. (%)
Fever 46 (78) 58 (86.6) 0.24
Shock 22 (37.5) 17 (25.4) 0.18
Renal insufﬁciency 13 (22) 6 (9) 0.05
Source, no. (%)
Abdomen 19 (32.2) 11 (16.9) 0.06
Venous catheter 14 (23.7) 30 (44.8) 0.02 0.42 (0.18–0.94), 0.035
Unknown 18 (30.5) 16 (23.9) 0.42
Urine 7 (12) 4 (6) 0.34
Positive culture from sites other than blood, no. (%)
Urine 15 (25.4) 12 (18) 0.38
Venous catheter 11 (18.6) 18 (27) 0.29
Respiratory samplea 4 (6.8) 10 (15) 0.16
Abdominal sampleb 3 (5.1) 4 (6) 1
Wound 2 (3.4) 7 (10.4) 0.17
Cardiac valve 1 (1.7) 0 0.47
Metastatic complications, no. (%)
Skin and soft tissue 2 (3.4) 4 (6) 0.68
Ocular 1 (1.7) 5 (7.5) 0.21
Lung 2 (3.4) 1 (1.5) 0.59
Endocarditis 1 (1.7) 1 (1.5) 1
Liver 0 1 (1.5) 1
Received antifungal therapy, no. (%) 38 (64.4) 55 (82) 0.03
Time to treatment (days), mean ± SD (median, range) 0.95 ± 3.7 (1, )12 to 8) 2.65 ± 5.1 (3,)1 to 19) 0.09
Catheter withdrawal, no. (%) 25 (42.4) 30 (44.8) 0.85
Mortality, no. (%) 36 (61) 30 (44.8) 0.07
Related mortality, no. (%) 18 (30.5) 5 (7.5) 0.16
HIV, human immunodeﬁciency virus; SD, standard deviation.
aRespiratory samples include sputum (six), tracheobronchial aspirate (six) and pleural ﬂuid (two).
bAbdominal samples include peritoneal ﬂuid (three) and intra-abdominal abscess drainage (four).
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p 0.01), the urinary tract as the portal of entry (5.6% vs.
21.7%; p 0.09) and venous catheter removal (28% vs. 65%;
p 0.007) were associated with a lower mortality rate. In the
multivariate analysis, corticosteroid treatment (OR 8.2; 95%
CI 1.1–61.9; p 0.04) and septic shock (OR 14.6; 95% CI 2.4–
90.2; p 0.004) proved to be independent risk factors for
death. The urinary tract as the portal of entry (OR 0.07, 95%
CI <0.01–0.8; p 0.03) and venous catheter removal (OR 0.06,
95% CI 0.01–0.4; p 0.002) were protective factors.
Discussion
C. tropicalis caused 6% of all episodes of fungaemia in our
institution during the study period. Patients with C. tropicalis
fungaemia were older, suffered more frequently from cancer,
and had a higher mortality rate than patients with fungaemia
caused by other species.
The proportion of candidaemia episodes caused by C. trop-
icalis varies widely with geographical area, ranging from 4%
to 24% of all episodes of candidaemia [5,6,8,21–23]. C. tropi-
calis accounts for up to 36% of episodes in South America,
the Middle East, and Southeast Asia [21–25]. By contrast, in
North America and Europe, C. tropicalis fungaemia usually
accounts for 4–16% of all episodes of candidaemia [5,6,8,12].
The reasons for these differences are not clear, although
they may be attributable to the greater use of ﬂuconazole in
hospitals in the USA and Europe [21,26], or to a widespread
clone of this species in the other countries [27–29].
In our institution, previous azole use was similar between
patients with C. tropicalis fungaemia and those with fungaemia
caused by other species (27% vs. 25%; p 0.7), although we
TABLE 4. Susceptibility of the 68 available Candida tropicalis strains
Antifungal drug No. of isolates
MIC (mg/L)
50% 90% Geometric mean Range of MICs
Amphotericin B 68 1 1 0.798 0.016–4
Fluconazole 68 0.25 2 0.965 0.06–8
Itraconazole 68 0.125 0.25 0.160 0.004–2
Voriconazole 68 0.03 0.125 0.049 0.004–0.5
Posaconazole 17 0.061 0.25 0.082 0.016–0.25
Caspofungin 29 0.06 0.25 0.092 0.006–0.5
Flucytosine 68 0.125 0.25 0.529 0.016–32
TABLE 5. Comparison between survivors and non-survivors among patients with Candida tropicalis fungaemia
Factor Non-survivors (n = 36) Survivors (n = 23) p Multivariate analysis, OR (95% CI), p
Age (years), mean ± SD (median, range) 61 ± 21 (67, 0–90) 55 ± 27 (68, 1–89) 0.31
Gender, no. (%)
Male 25 (69.84) 15 (65.2) 0.7
Female 11 (30.6) 8 (34.8)
Underlying disease, no. (%)
Cancer 19 (52.8) 9 (39.1) 0.42
Haematological disease 6 (16.7) 0 0.07
HIV 0 3 (13) 0.05
Injection drug use 0 4 (17.4) 0.02
Transplantation 3 (8.3) 0 0.27
Risk factor, no. (%)
Intensive-care unit 12 (33.3) 3 (13) 0.12
Neutropenia 7 (19.4) 0 0.03
Surgery 15 (41.7) 13 (56.5) 0.3
Parenteral nutrition 17 (47.2) 12 (52.2) 0.8
Intravenous lines 30 (83.3) 19 (82.6) 1
Bladder catheter 24 (66.7) 15 (65.2) 1
Previous antimicrobials 28 (77.8) 20 (87) 0.5
Previous antifungals 7 (19.4) 4 (17.4) 1
Previous azole agents 6 (16.7) 4 (17.4) 1
Corticosteroids 13 (36.1) 3 (13) 0.07 8.2 (1.1–61.9), 0.04
Clinical manifestations, no. (%)
Fever 27 (75) 19 (82.6) 0.54
Shock 18 (50) 4 (17.4) 0.01 14.6 (2.4–90.2), 0.04
Renal insufﬁciency 8 (22.2) 5 (21.7) 1
Source, no. (%)
Abdomen 14 (38.9) 5 (21.7) 0.25
Catheter 6 (16.7) 8 (34.8) 0.13
Unknown 13 (36.1) 5 (21.7) 0.38
Urine 2 (5.6) 5 (21.7) 0.09 0.07 (<0.01–0.8), 0.03
Received therapy, no. (%) 22 (61.1) 15 (65.2) 0.79
Time to treatment (days), mean ± SD (median, range) 0.5 ± 4.4 (2, )12 to 6) 1.6 ± 2.3 (1, )2 to 8) 0.38
Catheter withdrawal, no. (%) 10 (27.8) 15 (65.2) 0.007 0.06 (0.01–0.4), 0.002
HIV, human immunodeﬁciency virus; SD, standard deviation.
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were unable to demonstrate an accumulation of episodes
during the study period.
An association between C. tropicalis fungaemia and cancer
has been reported [12,21,25], although most studies included
only patients with cancer as an underlying disease or only
compared C. tropicalis fungaemia with C. albicans fungaemia
[16,21]. Our study is a better reﬂection of clinical practice,
as we compared an unselected population of patients with
C. tropicalis fungaemia with patients who had fungaemia
caused by other Candida species. C. tropicalis patients were
more likely to be older, suffer from cancer, and have the
abdomen as the portal of entry. Neutropenia was not associ-
ated with C. tropicalis, and a venous catheter was a less com-
mon source of this species. Our multivariate analysis showed
cancer and the abdomen as the portal of entry to be inde-
pendent risk factors for C. tropicalis fungaemia. Most of the
episodes of C. tropicalis fungaemia that we detected were
associated with gastrointestinal tumours and had an intra-
abdominal origin.
We found that the mortality rate during admission of
patients with C. tropicalis fungaemia was higher than that of
controls (61% vs. 44%; p 0.03), and similar data have been
reported by other authors [6,12]. In a population-based sur-
veillance study of candidaemia performed in Barcelona from
2002 to 2003, Almirante et al. [12] found that patients who
had C. tropicalis fungaemia were more likely to die within
30 days than those who did not (59% vs. 42%; p 0.06). On
comparison of survivors with non-survivors in an intensive-
care cohort, the isolation of C. tropicalis increased the risk of
dying 2.6-fold, although the difference did not reach statisti-
cal signiﬁcance (p 0.09) [6].
We found that corticosteroid therapy and septic shock
were independent risk factors for mortality. The urinary
tract as the portal of entry and removal of the venous cathe-
ter proved to be protective factors. These results agree with
those of other studies that have analysed risk factors for
in-hospital mortality among patients with candidaemia caused
by all types of Candida species [6,30]. In a hospital cohort,
the independent determinants of mortality were corticoste-
roid use, increasing APACHE II score, inadequate initial
ﬂuconazole dosing, and retention of a central venous cathe-
ter [30]. In an intensive-care cohort, the mortality rate was
higher when the central venous catheter was removed
‡2 days after the diagnosis of candidaemia (60.9% vs. 39.4%
with removal within 1 day; p 0.04) [6].
The limitations of our study include its retrospective
design. However, cases and controls were representative of
the general population of patients with fungaemia at our
hospital during the study period. The small number of
patients may limit the conclusions that can be drawn about
the prognostic factors. However, as we mentioned above,
fungaemia caused by C. tropicalis is not very prevalent in Eur-
ope. In a large population-based study, C. tropicalis caused
only 10% of 345 episodes of candidaemia [12], and in the
intensive-care cohort of Leroy et al. [6], only 15 (4.9%) of
the 271 invasive candidiasis episodes were caused by C. tropi-
calis. So, to our knowledge, this is the largest series of
C. tropicalis fungaemia from Europe. Another issue is that we
did not perform superﬁcial cultures to check for Candida col-
onization, so we could not determine whether prior superﬁ-
cial colonization was more common among patients who
developed C. tropicalis fungaemia.
C. tropicalis is a relevant cause of fungaemia, and should
alert physicians to the possibility of underlying malignancy,
abdominal origin, and poor prognosis.
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